Propiolactone

Propiolactone (β-propiolactone; 2-Oxetanone) is a viral chemical inactivator that causes the infectious inactivation of viruses. Propiolactone was co-incubated with SARS-CoV at a ratio of 1:1000 (v:v) and used as a bacteriostatic agent to formulate the BPL-inactivated influenza virus vaccine (Flu-BPL)^[1][2]. IC50 & Target:SARS-CoV-2^[1] In Vitro:Propiolactone (β-propiolactone) can be used for vaccine purification. After cells were harvested by low-speed centrifugation, SARS-CoV was chemically inactivated with Propiolactone (1:1000 v:v). Propiolactone was incubated with SARS-CoV for 24 h at 4°C. A second incubation at room temperature was performed to hydrolyze residual propiolactone. and concentration of the vaccine. Following BPL inactivation. a polvethylene glycol-sodium chloride (PEG-NaCl) mixture was added to precipitate the inactivated virus. After cen and concentration of the vaccine. After propiolactone inactivation, a polyethylene glycol-sodium chloride (PEG-NaCl) mixture is added to precipitate the inactivated virus. Finally, Propiolactone (1:10000 v:v) was added as a bacteriostatic agent.
Propiolactone-inactivated virus loses infectivity in Vero cells^[1].
Note: Propiolactone is unstable in water and prone to hydrolysis. It should be used immediately after being dissolved in water. In Vivo:Mice were immunized with propiolactone (β-propiolactone)-inactivated influenza A virus (~25 mg total protein per dose; intramuscular injection). SARS is non-lethal in young BALB/c mice after propiolactone inactivation treatment. Although the virus replicated in the respiratory tract of the mice, it was cleared by day 5. Propiolactone treatment yielded 1.5 μg of total hemagglutinin protein, which was negative after infection of mice^[1].